TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement previously announced on December 19, 2025 (the “Offering”) in order to accommodate participation by a long-term existing investor. The Company will now raise gross proceeds of up to US$6.45 million in the Offering, through the issuance of up to 921,428 common shares at a price of US$7.00 per common share. The common shares sold pursuant to the Offering will be subject to a hold period of four months plus one day from the closing date of the Offering. The closing of the Offering is expected to occur on or prior to December 30, 2025. The Company intends to use the net proceeds from the Offering for expansion of its sales and marketing,...

PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it received an Incomplete Letter from the United States Food and Drug Administration (FDA) on December 23, 2025 for its Re-Tain® New Animal Drug Application (NADA), and simultaneously that it is increasing its First Defense® field sales force by 50% and expanding its First Defense® manufacturing capabilities. In seeking FDA approval to bring its innovative Re-Tain® product to market, ImmuCell received Complete Letters from the FDA for four of the five Technical Sections required for NADA approval. It pursued a two-pronged manufacturing approach to reduce capital expenditure and limit technical...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) — Hampton Financial Corporation (“Hampton” or the “Company”, TSXV: HFC) announces that it has reached agreements to settle all obligations under Hampton debentures in the aggregate principal amount of $4 million, and to settle a quarterly interest payment under Hampton debentures in the aggregate principal amount of $5.2 million, in exchange for the issuance to the debenture holders of subordinate voting shares of Hampton at the deemed price of $0.40 per share. Hampton expects that the debt settlement transactions will close on or before December 31, 2025 and would result in the issuance of an aggregate of 10,528,141 subordinate voting shares to the debenture holders. The transactions are subject to the...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) — Copper Road Resources Inc. (TSX-V: CRD) (“Copper Road Resources” or the “Company“) is pleased to announce that it has closed the first tranche (the “First Tranche”) of its previously announced non-brokered private placement (the “Offering”) consisting of the sale of 9,952,447 flow-through units ( the “FT Units”) at a price of $0.045 per FT Unit and 2,435,000 hard-dollar units (the “Units”) at a price of $0.04 per Unit for aggregate gross proceeds of $545,260. Each Unit consists of one common share of the Company and one common share purchase warrant (each, a “Warrant”). Each FT Unit consists of one common share and one Warrant of the Company each to be issued as a “flow-through...

Primary Mortgage Market Survey®U.S. weekly average mortgage rates as of 12/24/2025MCLEAN, Va., Dec. 24, 2025 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) today released the results of its Primary Mortgage Market Survey® (PMMS®), showing the 30-year fixed-rate mortgage (FRM) averaged 6.18%. “The average 30-year fixed-rate mortgage decreased further this week,” said Sam Khater, Freddie Mac’s Chief Economist. “Declining rates offer a timely and welcome gift for aspiring homebuyers.”   News FactsThe 30-year FRM averaged 6.18% as of December 24, 2025, down from last week when it averaged 6.21%. A year ago at this time, the 30-year FRM averaged 6.85%. The 15-year FRM averaged 5.50%, up from last week when it averaged 5.47%. A year ago at this time, the 15-year FRM averaged 6.00%.The PMMS® is focused on conventional, conforming,...

Hangzhou, China, Dec. 24, 2025 (GLOBE NEWSWIRE) — WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that it will effect a reverse stock split of its ordinary shares on a 1-for-100 basis (the “Reverse Stock Split”). The Company’s Class A ordinary shares will begin trading on a post-split basis when the market opens on December 29, 2025. The Company’s Class A ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol “WOK,” with a new CUSIP number G9767H125. The Reverse Stock Split has been approved by the Company’s shareholders and the Company’s board of directors, and is being effectuated primarily to maintain...

TUCSON, Ariz., Dec. 24, 2025 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that it has entered into a definitive agreement for a private placement financing of up to $50.0 million aggregate principal amount of senior secured notes due 2028 together with warrants to purchase common stock of the Company. WestPark Capital Inc. served as Sole Placement Agent. The Company expects to issue an initial $15.0 million principal amount of notes at closing with the option to fund up to an additional $35.0 million principal amount in one or more tranches subject to certain conditions. The notes will be senior secured obligations of the Company. The...

VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) — Westhaven Gold Corp. (TSX-V: WHN) (“Westhaven” or the “Company”) announces that, pursuant to the terms of the Company’s Stock Option Plan, Westhaven has granted 400,000 incentive stock options to an Officer of the Company. The options are exercisable at CDN$0.25 per share and can be exercised until December 23, 2030.  Following this grant of stock options there are 16,805,000 stock options outstanding, representing 6.9% of the Company’s issued and outstanding common shares. Investor Relations Agreement with Peterson Capital The Company is also announcing, effective January 1, 2026, it has entered into a consulting agreement (the “Agreement”) with Grignan Holdings Ltd. dba Peterson Capital (“Peterson Capital”) to provide investor relations services in compliance...